Oncology company Turning Point seeking $100M IPO

Five months after raising an $80 million mezzanine round, cancer company Turning Point is aiming to reap $100 million in a NASDAQ listing that will fund a registrational trial.

Turning Point Therapeutics Inc. (San Diego, Calif.) is developing a cancer pipeline designed to tackle treatment resistances that emerge from available therapies (see "Ahead of Phase II, TP Raises $80M Mezzanine Round")...